Canada · Delayed Price · Currency is CAD Cannara Biotech Earnings Call Transcripts
Fiscal Year 2026
-
Q2 saw revenue rise to CAD 27.2M with strong margins and market share gains, especially in Quebec, despite industry seasonality. Strategic investments, new product launches, and capacity expansion position the business for continued growth and international opportunities.
-
Disciplined growth, strong brand portfolio, and operational efficiency have driven rising market share and profitability, with a clear, capital-efficient expansion plan and robust financials. Strategic capital raises and TSX uplisting aim to enhance liquidity and investor access.
-
Record Q1 2026 results with 20% net revenue growth year-over-year, 45% gross margin, and strong cash flow. Market share leadership in Quebec and national gains driven by premium product launches and disciplined expansion.
Fiscal Year 2025
-
Fiscal 2025 set new records in revenue, profit, and cash flow, driven by expanded capacity and operational efficiency. Market share surged across key provinces, with leadership in several product categories. Continued growth and margin improvement are expected as further expansion comes online.
-
Operating two major Quebec facilities, the company is profitable, cash flow positive, and rapidly scaling production. With strong brand loyalty in Quebec, a focus on genetics, and new vape products launching, it targets further growth while maintaining disciplined inventory and expansion strategies.
-
A leading vertically integrated cannabis producer in Quebec reported record financial results, strong market share growth, and operational efficiencies. Strategic facility investments and proprietary genetics drive scalable expansion, with a focus on premium products and disciplined capital management.
-
Q3 2025 delivered record revenue, profit, and cash flow, driven by operational breakthroughs and expanded capacity. Quebec market share surged, and national share grew despite competitive pressures. Focus remains on disciplined expansion, margin leadership, and innovation.
-
A vertically integrated cannabis producer is rapidly expanding capacity and market share, especially in Quebec, while maintaining strong financial performance and margins. Strategic investments in genetics, operational efficiency, and brand leadership drive growth, with expansion funded by internal cash flow and debt.
-
Record Q2 results with 35% year-over-year revenue growth, industry-leading margins, and expanding market share in key categories. Capacity is scaling to meet demand, with a focus on Canadian market leadership and high ROI investments.
Fiscal Year 2024
-
Achieved strong fiscal 2024 results with 43% revenue growth, positive EBITDA, and rising market share. Expansion plans target 100,000 kg annual capacity and 10% national market share, driven by brand leadership, innovation, and operational efficiency.
-
Q3 2024 saw CAD 19.5M revenue, 29.4% gross margin, and 2M net income, with strong market share gains in Quebec and a focus on scaling production and sales nationally. Expansion plans target 75,000 kg annual capacity by 2028, with continued investment in innovation and efficiency.